Vaccinology: Principles and Vaccine Types

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Vaccine selection hinges on matching the required immune response (humoral, cell-mediated, or mucosal) to the vaccine platform's capabilities; modified live vaccines (MLVs) induce robust cell-mediated immunity by replicating within host cells and engaging MHC class I pathways, while killed vaccines primarily elicit humoral responses via MHC class II presentation.
• Adjuvants are critical for enhancing vaccine immunogenicity by activating innate immune pathways and providing a depot effect; aluminium salts promote Th2-biased humoral responses, whereas novel adjuvants like TLR agonists and emulsions can broaden immune quality and duration, including cell-mediated immunity.
• Modified live vaccines (MLVs) mimic natural infection and often require a single dose due to sustained antigenic stimulation, but pose risks of reversion to virulence and are contraindicated in immunocompromised or pregnant animals; killed and subunit vaccines are safer but necessitate multiple doses and adjuvants for adequate protection.
• Emerging mRNA vaccine platforms offer rapid development and potent immune responses by enabling host cells to produce antigens endogenously, combining the safety of non-replicating vaccines with the MHC class I presentation of MLVs.
• Antigenic variation, such as drift and shift in influenza viruses, necessitates regular vaccine updates and careful strain matching to maintain efficacy, as circulating strains can diverge from vaccine strains, leading to reduced protection.
• Practical vaccine selection involves assessing pathogen biology (e.g., requirement for cell-mediated immunity), host factors (age, immune status, pregnancy), and production system constraints, with a critical consideration for the risk of vaccine-associated adverse events like injection-site sarcomas in cats.

Vaccination remains the most cost-effective medical intervention in veterinary practice, yet the rational use of vaccines demands more than familiarity with product labels. This article provides the conceptual foundation for vaccine selection and evaluation across species, serving veterinary students who must integrate immunology with clinical decision-making. It addresses how vaccines engage the immune system, how different vaccine platforms exploit distinct immunological pathways, and how adjuvants shape the quality and duration of protective responses. Specific schedules and individual disease vaccines are outside the scope of this reference.

The central clinical question is also which vaccine to administer, but which immune response a given patient or population requires. A vaccine that excels at generating humoral immunity may fail against pathogens that require cell-mediated clearance. Understanding the mechanistic basis of vaccine types allows the clinician to interpret product claims, anticipate adverse events, and explain to clients why revaccination intervals exist. The principles presented here apply across companion animal, livestock, and wildlife medicine, though practical constraints differ substantially between production systems and regions.

At a Glance

The Immunological Basis of Vaccination

Vaccination exploits the defining features of adaptive immunity: specificity, memory, and self-limitation. A vaccine presents antigen in a context that mimics infection sufficiently to trigger clonal expansion of lymphocytes, yet without causing disease. The resulting memory B and T cell populations persist and respond rapidly upon subsequent encounter with the pathogen.

The quality of the immune response depends on how antigen is delivered, processed, and presented. Extracellular antigens are taken up by antigen-presenting cells and presented on MHC class II molecules to CD4+ helper T cells, which drive antibody production. Intracellular antigens, whether from replicating viruses or cytosolic delivery, are processed onto MHC class I and recognized by CD8+ cytotoxic T cells. This dichotomy explains why vaccine platform selection is clinically consequential: a killed vaccine that cannot access the cytosolic pathway will not generate robust cytotoxic T cell responses, whereas a replicating vaccine can.

Protective immunity is not a single entity. For many pathogens, neutralising antibody alone is sufficient. For intracellular bacteria, viruses that spread cell-to-cell, and certain parasites, cell-mediated immunity is essential. The WOAH terrestrial animal health standards recognize that vaccination strategies must be tailored to the epidemiology and immunobiology of each target disease, and the same principle applies at the level of the individual patient.

Innate Immune Activation and the Adjuvant Concept

Adaptive immune responses do not begin spontaneously. They require innate immune signals that upregulate costimulatory molecules and inflammatory cytokines. Adjuvants provide these signals. An adjuvant is any substance incorporated into a vaccine that enhances the magnitude, breadth, or durability of the immune response to the co-administered antigen.

Aluminium salts remain the most widely used adjuvants in veterinary and human vaccines, with a record of safe and effective use spanning more than six decades. Their mechanism is more complex than the historical depot theory suggested. Aluminium adjuvants activate the NLRP3 inflammasome, promote antigen uptake by dendritic cells, and reliably skew responses toward a Th2 phenotype with strong antibody production. As Lindblad's retrospective analysis of aluminium adjuvants notes, the detailed mode of action is still not completely understood, and optimizing their use in new formulations remains partly empirical.

The limitations of aluminium are equally important. They are poor inducers of cell-mediated immunity and do not consistently generate mucosal IgA. For pathogens where these responses are critical, alternative adjuvant systems are needed. Modern adjuvants include oil-in-water emulsions, Toll-like receptor agonists such as CpG motifs and monophosphoryl lipid A, and saponin-based combinations. These systems act through distinct innate pathways and can broaden the antibody repertoire, enhance T cell responses, and improve immunogenicity in populations with waning immunity. The review of adjuvants in licensed vaccines by Del Giudice and colleagues demonstrates that these newer formulations induce early innate activation that translates into higher antibody and cellular responses, and in some cases confer protection against heterologous strains not contained in the vaccine.

Modified Live Vaccines

Modified live vaccines (MLVs) contain pathogens that have been attenuated through serial passage, chemical mutagenesis, or targeted genetic modification. They retain the capacity to replicate in the host, usually to a limited extent, and thereby mimic many features of natural infection. Antigen is produced endogenously, enters the MHC class I pathway, and stimulates cytotoxic T cell responses alongside humoral immunity. A single dose often suffices for primary immunization because the replicating organizm provides sustained antigenic stimulation.

The clinical advantages of MLVs are substantial, but so are their constraints. They can cause disease in immunocompromised patients, pregnant animals, or species for which the attenuation is insufficient. They require careful cold-chain management, as heat and light degrade the live organizm. Reversion to virulence is a theoretical concern that has been documented for some pathogens. The review of PRRSV pathogenesis and immune interaction illustrates the difficulty of developing effective MLVs against pathogens that subvert the immune response, and highlights the gaps in knowledge that still limit vaccine design for such agents.

Killed and Subunit Vaccines

Killed vaccines contain whole inactivated pathogens, while subunit vaccines contain purified antigenic components. Both are non-replicating and therefore cannot cause infection, making them appropriate for immunocompromised patients and pregnant animals. Their safety profile is their principal advantage.

The immunological cost is considerable. Non-replicating antigens are processed through the exogenous pathway, generating primarily humoral immunity. They require adjuvants, multiple doses for primary series, and regular boosters to maintain protective antibody titres. Mucosal immunity is poorly induced by parenteral administration of killed vaccines. For pathogens that require cell-mediated clearance, killed vaccines are often inadequate regardless of adjuvant formulation.

Emerging Platforms and Antigenic Variation

mRNA vaccines represent a fundamentally different approach. instead of delivering antigen directly, they deliver the genetic instructions for antigen synthesis, allowing host cells to produce the immunogen endogenously. This platform combines the safety of a non-replicating vaccine with the MHC class I presentation of a live vaccine. The review of mRNA vaccines by Pardi and colleagues describes their high potency, capacity for rapid development, and potential for low-cost manufacture, while acknowledging that instability and inefficient delivery were historically limiting factors that recent technological advances have largely overcome.

Antigenic variation remains a persistent challenge across species. Influenza viruses undergo continuous antigenic drift and sporadic antigenic shift in their surface glycoproteins, forcing regular vaccine updates. The review of continuing challenges in influenza notes that structural analysis has revealed common epitopes across influenza viruses, suggesting that a universal vaccine may eventually be possible. Until then, veterinary clinicians must account for strain matching when selecting vaccines for production species and must recognize that vaccine efficacy can decline as circulating strains diverge from vaccine strains.

Selecting Vaccine Types in Practice

The choice between modified live, killed, subunit, and emerging vaccine platforms rests on a structured assessment of the patient, the pathogen, and the production system. No single platform is universally superior. The decision framework begins with three questions: what immune response is required for protection, what is the infection risk profile of the individual or group, and what are the consequences of vaccine-associated adverse events in this specific context.

Pathogen Biology and Immune Correlates

The first decision point is whether the pathogen requires cell-mediated immunity for clearance. Intracellular pathogens, including viral agents such as PRRSV, demand a robust cytotoxic T cell response that killed vaccines typically fail to generate. Modified live vaccines replicate within host cells and present endogenous antigens through MHC class I, a pathway that more faithfully mimics natural infection. For pathogens where neutralising antibody is the primary correlate of protection, killed or subunit vaccines are often sufficient and carry a lower risk profile.

Antigenic variation changes the calculus. Influenza viruses undergo continuous antigenic drift in their surface glycoproteins, which forces regular vaccine updates and complicates cross-protection. Where antigenic diversity is high, vaccines that induce broad, cross-reactive responses are preferred. Some adjuvant systems broaden the antibody repertoire beyond the specific strains included in the vaccine, a property documented for oil-in-water emulsions in human influenza vaccines. The same principle applies in veterinary species where multiple strains or serotypes circulate.

Host Factors That Change the Decision

Age and immunological maturity are decisive. Neonates with maternal antibody interference respond poorly to modified live vaccines, as passively acquired antibody neutralises the vaccine virus before replication can occur. Killed vaccines are less affected by maternal antibody but require multiple doses and adjuvants to achieve protective responses. In young animals, the timing of the first dose must balance maternal antibody decay against the window of susceptibility.

Immunocompromised patients, whether from concurrent disease, malnutrition, or drug therapy, should not receive modified live vaccines. The vaccine strain can revert to virulence or cause disease in the absence of an intact immune system. Killed vaccines are safe in these patients but may produce suboptimal responses. Pregnant animals present a specific contraindication for many modified live vaccines because of the risk of transplacental infection and fetal damage. The product label must be consulted for each vaccine, as contraindications vary by product and species.

Production system and economic context alter the risk-benefit calculation. In high-density swine operations where PRRSV is endemic, the cost of reproductive failure and mortality justifies vaccination even when the immune response is imperfect. In low-prevalence regions or valuable breeding stock, the risk of vaccine-associated disease may outweigh the benefit. The same vaccine can be a rational choice in one herd and an unacceptable risk in another.

Adjuvant Selection and Formulation

Adjuvants are not inert carriers. They shape the quality, magnitude, and duration of the immune response through direct activation of innate immunity. Aluminium salts remain the most widely used adjuvants in veterinary vaccines, with a documented record of inducing early, efficient, and long-lasting protective immunity. Their mechanism of action is incompletely understood, but they are recognized as Th2-biasing adjuvants that favour humoral responses. This makes them appropriate for antigens where antibody is the protective mechanism, but limiting for pathogens requiring cellular immunity.

Newer adjuvant systems combine multiple components to activate different innate immune pathways. Toll-like receptor agonists, oil-in-water emulsions, and saponin-based formulations can each be combined with aluminium salts to broaden the response. These systems induce early innate activation that translates into higher antibody titres and cellular responses, and some broaden the specificity of the response to cover heterologous strains. The choice of adjuvant must be matched to the antigen and the target species, as adjuvant performance varies across species and even across routes of administration.

Vaccine Type Comparison

Monitoring Vaccine Response and Failure

Vaccine failure is not a single entity. The diagnostic sequence begins with distinguishing true vaccine failure from improper handling, inappropriate timing, or unrealistic expectations. Serological monitoring can confirm seroconversion, but antibody titres do not always correlate with protection. For diseases where cell-mediated immunity is the protective mechanism, serology may be misleading.

The first step in investigating suspected vaccine failure is to verify the cold chain. Modified live vaccines are particularly sensitive to temperature excursions, and a single episode of warming can inactivate the vaccine while leaving it visually unchanged. Next, review the administration technique. Subcutaneous vaccines given intramuscularly, or vaccines given to animals with intercurrent disease, may fail to immunize. Finally, consider whether the vaccine strain matches the circulating field strain. Antigenic drift in pathogens such as influenza can render existing vaccines less effective against emerging variants.

Documentation of vaccination is a professional obligation. The record should include the product name, batch number, route, site, dose, and the identity of the animal or group. In production systems, this documentation supports herd health decisions and may be required for trade certification under international animal health standards. The World Organization for Animal Health maintains terrestrial animal health standards that address vaccination in the context of disease surveillance and international movement of animals.

Species-Specific Considerations

The same vaccine platform can behave differently across species. Adjuvants that are well tolerated in cattle may cause injection-site reactions in cats. The route of administration that is practical in a feedlot is not feasible in a pet bird. Production species tolerate repeated handling for booster doses, while companion animal practice prioritizes minimizing the number of visits. These constraints are as important as immunology in the final vaccine selection.

In swine, PRRSV vaccination illustrates the gap between vaccine availability and protective efficacy. The virus modulates the host immune response, and current vaccines provide incomplete protection against heterologous strains. This is an area where the evidence base is contested, and veterinarians must weigh the partial protection offered by vaccination against the cost and the risk of promoting false confidence in herd immunity. The same caution applies to other pathogens with high antigenic variability where vaccine efficacy is strain-dependent.

Recognized Complications and Early Detection

Vaccine adverse events range from transient injection-site reactions to rare anaphylactic episodes. The most common complications are local inflammation, mild pyrexia, and transient lethargy, which typically resolve within 24 to 72 hours. More serious events include vaccine-associated sarcomas in cats, immune-mediated hemolytic anemia following certain modified live vaccines, and inadvertent infection of immunocompromised or pregnant animals with attenuated organizms.

Early detection depends on owner communication and scheduled re-examination. Instruct clients to monitor injection sites for swelling beyond 2 cm, persistent pain, or ulceration. For cats, any mass at a vaccine site persisting beyond three months, growing beyond 2 cm, or enlarging one month after injection warrants aspiration or biopsy. Systemic signs such as vomiting, facial edema, urticaria, or collapse within minutes to hours of vaccination indicate anaphylaxis and require immediate intervention.

Vaccine failure presents differently. A vaccinated animal that develops the target disease suggests either inadequate immunization, antigenic mismatch, or interference from maternal antibodies. Serological testing can distinguish between these possibilities when validated assays exist. For example, measuring antibody titres in young animals helps identify maternal antibody interference, while viral sequencing can reveal whether field strains differ from vaccine strains, as documented for porcine reproductive and respiratory syndrome virus in swine populations PRRSV pathogenesis and immune interaction review.

Common Errors and Corrective Actions

Less experienced clinicians frequently misjudge the timing of booster intervals. Extending intervals beyond the labelled duration risks gaps in protection, while unnecessary boosters add cost and adverse event risk without benefit. Consult the current product label and species-specific guidelines from professional bodies such as the AVMA practice resources before recommending a schedule.

A second common error involves administering modified live vaccines to pregnant animals or those receiving immunosuppressive therapy. Attenuated organizms can revert to virulence or cause fetal infection. Always confirm pregnancy status and review the medication history before vaccination. When in doubt, use a killed or subunit product.

A third error is assuming that all adjuvanted vaccines behave identically. Aluminium salts, oil-in-water emulsions, and combination adjuvants differ substantially in their immune polarisation and reactogenicity profiles. Aluminium adjuvants predominantly promote Th2-type responses, which may be suboptimal for intracellular pathogens aluminium adjuvants in retrospect and prospect. Selecting an adjuvant system should follow the target pathogen's immune correlates, not habit.

Limitations of Current Evidence

The evidence base for many veterinary vaccines rests on challenge studies and field trials with limited statistical power. Correlates of protection are well defined for some diseases, such as canine distemper and feline panleukopenia, but poorly defined for others, including PRRS and equine influenza. For influenza, continuous antigenic drift forces frequent vaccine updates, and cross-protection against heterologous strains remains inconsistent continuing challenges in influenza.

Expert opinion diverges on several points. The duration of immunity for many killed vaccines is unknown beyond the labelled interval. Whether annual revaccination is necessary or whether extended intervals suffice remains contested for some companion animal vaccines. Similarly, the role of mucosal immunity in protection against respiratory pathogens is acknowledged but rarely measured in practice. Adjuvant mechanisms are still incompletely understood, the empirical optimization of aluminium formulations persists despite decades of use aluminium adjuvants in retrospect and prospect.

Referral, Consultation, and Reporting

Referral to a specialist is warranted when a vaccine-associated adverse event is severe, recurrent, or unexplained. Suspected vaccine-induced immune-mediated disease, angioedema, or anaphylaxis despite premedication should prompt consultation with an internal medicine specialist. Dermatologists or surgical oncologists should evaluate suspected injection-site sarcomas before excision to plan margins.

Laboratory involvement is appropriate when vaccine failure is suspected. Paired acute and convalescent serology, pathogen detection by PCR, and viral isolation can confirm breakthrough infection. Reference laboratories may also perform adverse event genotyping for suspected reversion to virulence.

Regulatory reporting obligations vary by jurisdiction. Many countries require notification of serious adverse events to the national pharmacovigilance authority. The WOAH terrestrial animal health standards also mandate reporting of certain notifiable diseases, even when they occur in vaccinated animals. Clinicians should know their local reporting requirements and document all adverse events in the medical record, including lot number, route, and time of onset.

Frequently Asked Questions

How do I choose between a modified live and a killed vaccine when both are licensed for the same pathogen?

The decision rests on the host's immune status, the production system's disease history, and the consequences of vaccine-associated adverse events. Modified live vaccines generally induce broader humoral and cell-mediated responses that more closely mimic natural infection, which is advantageous in outbreak settings where rapid protection is needed. Killed vaccines carry no reversion-to-virulence risk and are safer in immunocompromised animals, pregnant stock where label restrictions permit, and naive populations. Consult the label and current formulary for species-specific contraindications. When the pathogen shows marked antigenic variation, as with PRRSV, the match between vaccine strain and field strain may matter more than vaccine type, and neither platform reliably cross-protects against heterologous strains (PRRSV pathogenesis and immune interaction review).

What should I do when cold chain reliability is uncertain in the field?

Modified live vaccines are the most cold-chain dependent products because lyophilised organizms must be reconstituted with diluent at the correct temperature and used within a short window, often one to two hours. If refrigeration is unreliable, select killed or subunit vaccines that tolerate temperature excursions better, though they still degrade with prolonged heat exposure. Carry vaccines in insulated containers with phase-change materials instead of ice alone, and monitor with a data logger. Discard any reconstituted vaccine that is not used within the labelled time. Record temperature deviations and report them to the manufacturer, since the clinical consequence of a heat-damaged vaccine is silent vaccine failure instead of an acute adverse event. The MSD Veterinary Manual provides species-specific guidance on vaccine storage and handling.

How do I document vaccination in a way that supports herd health decisions and regulatory compliance?

Record the product name, serial or lot number, route, dose, site, date, and the identity of every animal or group vaccinated. Note the animal's age, body condition, and any concurrent illness. Keep the records in a format that allows rapid retrieval during a disease investigation, and retain them for at least the period required by local regulations. For animals moving across borders, vaccination records must align with the WOAH terrestrial animal health standards, which specify which vaccines are recognized for trade purposes and what documentation is accepted. In herd outbreaks, record the interval between vaccination and challenge, since this determines whether a case represents vaccine failure or a break in coverage.

How do I explain a vaccine failure to a client without undermining confidence in the program?

Frame the discussion around the distinction between vaccine failure and vaccine ineffectiveness. A vaccine can fail because of poor storage, incorrect administration, maternal antibody interference, or infection before immunity develops. It can also be ineffective because the circulating strain is antigenically distant from the vaccine strain, a recognized limitation for variable pathogens such as influenza and PRRSV (continuing challenges in influenza). Present the investigation as a systematic review of handling, timing, and strain match instead of a single cause. Emphasize that no vaccine provides sterile immunity or complete protection for every individual, and that population-level benefits depend on high coverage. Offer concrete next steps, such as serological testing or revaccination with a different platform.

What are the practical limits of adjuvanted vaccines in small animal practice?

Aluminium-adjuvanted vaccines are widely used and have a long safety record, but they skew responses toward Th2-type immunity and may be less effective for pathogens requiring cell-mediated clearance (aluminium adjuvants in retrospect and prospect). Local injection-site reactions, including sterile abscesses and granulomas, occur more often with adjuvanted products than with modified live vaccines. In cats, the historical association between injection-site sarcomas and adjuvanted vaccines has driven a shift toward non-adjuvanted products for feline leukemia virus and rabies, although the causal relationship remains debated. When an adjuvanted vaccine is the only option, inject subcutaneously in a distal limb where a sarcoma would be surgically resectable, and record the exact site. Monitor injection sites at subsequent visits and document any persistent swelling beyond three weeks.

How do vaccination principles differ when moving from companion animals to food animals?

Food animal practice adds the dimensions of cost per dose, labor efficiency, and withdrawal intervals. A vaccine that is immunologically superior but requires individual handling may be impractical in a 2,000-head feedlot, where mass administration through water or injectable systems is standard. Withdrawal periods for vaccine excipients and adjuvants must be checked against the label and local regulations before marketing animals. Herd-level immunity, not individual protection, is the primary goal, and vaccination timing is coordinated with production cycles such as weaning and transport. The economic threshold for vaccine use is lower in food animals, so justify recommendations with expected reductions in morbidity, mortality, or treatment costs. The AVMA practice resources offer guidance on professional obligations in production animal settings.

Related Clinical & Scientific Guides

• Hypersensitivity Reactions: Types and Mechanisms
• Therapeutic Decision-Making for Respiratory Infections in Cattle
• Monitoring Fluid Therapy in Critically Ill Veterinary Patients

References and Further Reading

• mRNA vaccines - a new era in vaccinology.. 2018.
• Aluminium adjuvants--in retrospect and prospect.. 2004.
• Porcine Reproductive and Respiratory Syndrome Virus (PRRSV): Pathogenesis and Interaction with the Immune System.. 2016.
• Correlates of adjuvanticity: A review on adjuvants in licensed vaccines.. 2018.
• Continuing challenges in influenza.. 2014.
• Porcine reproductive and respiratory syndrome virus: an update on an emerging and re-emerging viral disease of swine.. 2010.
• Davis-Thompson Foundation Veterinary Pathology Resources. Davis-Thompson Foundation.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.

Related Articles

• Immunohistochemistry in Veterinary Diagnostics: Principles and Protocols
• Hypersensitivity Reactions: Types and Mechanisms
• Acute Inflammation: Vascular and Cellular Events
• Adaptive Immunity: B Cell and T Cell Responses
• Autoimmunity: Mechanisms and Veterinary Examples

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.